BE Study of Naftifine HCL

Exclusion Criteria

• •1. Pregnant or lactating or planning to become pregnant during the study period
• •2. Use of antipruritics, including antihistamines, within 72 hours prior to entry into the study
• •3. Use of topical corticosteroid, antibiotics or antifungal therapy within 2 weeks prior to entry into the study
• •4. Use of systemic (e.g., oral or injectable) corticosteroid, antibiotics or antifungal therapy within 1 month prior to entry into the study
• •5. Use of oral terbinafine or itraconazole within 2 months prior to entry into the study
• •6. Use of immunosuppressive medication or radiation therapy within 3 months prior to entry into the study.
• •7. Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.
• •8. Presence of any other infection of the foot or other disease process that might confound the treatment evaluation
• •9. History of dermatophyte infections unresponsive to systemic or topical antifungal drugs
• •10. Known hypersensitivity to Naftifine Hydrochloride or to any component of the formulation